ISCOMATRIX™ adjuvant promotes epitope spreading and antibody affinity maturation of influenza A H7N9 virus like particle vaccine that correlate with virus neutralization in humans.

@article{Chung2015ISCOMATRIXAP,
  title={ISCOMATRIX™ adjuvant promotes epitope spreading and antibody affinity maturation of influenza A H7N9 virus like particle vaccine that correlate with virus neutralization in humans.},
  author={Ka Yan Chung and Elizabeth M. Coyle and Dewal Jani and Lisa R. King and Rukmini Bhardwaj and Louis F Fries and Gale E. Smith and Gregory Melvin Glenn and H. Golding and Surender Khurana},
  journal={Vaccine},
  year={2015},
  volume={33 32},
  pages={3953-62}
}
In a previously reported phase I clinical trial, subjects vaccinated with two doses of an unadjuvanted H7N9 virus like particle (VLP) vaccine responded poorly (15.6% seroconversion rates with 45μg hemagglutinin (HA) dose). In contrast, 80.6% of subjects receiving H7N9 VLP vaccine (5μg HA) with ISCOMATRIX™ adjuvant developed hemagglutination-inhibition (HI) responses. To better understand the role of adjuvant, complete antibody epitope repertoires of post-vaccination sera were investigated using… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 2 times. VIEW TWEETS